Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin + factor VIII concentrate versus factor VIII concentrate alone for minor procedures in non-severe hemophilia A
NL-OMON47789Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2018
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of desmopressin and Factor VIII in hemophilia A (2 arms), sponsored by Erasmus MC. Primary endpoints: Average deviation of measured pre-intervention FVIII level from predicted peak FVIII value and Factor VIII concentrate consumption in first 24 hours. Started Jan 2018; status: active, not recruiting.
02
Drugs
desmopressinFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON47789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47789.